ES2187443T3 - Compuestos de hidroxamato inverso como inhibidores de metaloproteasas matriciales. - Google Patents

Compuestos de hidroxamato inverso como inhibidores de metaloproteasas matriciales.

Info

Publication number
ES2187443T3
ES2187443T3 ES00905758T ES00905758T ES2187443T3 ES 2187443 T3 ES2187443 T3 ES 2187443T3 ES 00905758 T ES00905758 T ES 00905758T ES 00905758 T ES00905758 T ES 00905758T ES 2187443 T3 ES2187443 T3 ES 2187443T3
Authority
ES
Spain
Prior art keywords
group
alkyl
carbon
hydrogen
metaloproteases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00905758T
Other languages
English (en)
Spanish (es)
Inventor
Michael L Curtin
Yujia Dai
Steven K Davidsen
Howard R Heyman
James H Holmes
Michael R Michaelides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2187443T3 publication Critical patent/ES2187443T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES00905758T 1999-01-27 2000-01-27 Compuestos de hidroxamato inverso como inhibidores de metaloproteasas matriciales. Expired - Lifetime ES2187443T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23908799A 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
ES2187443T3 true ES2187443T3 (es) 2003-06-16

Family

ID=22900549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00905758T Expired - Lifetime ES2187443T3 (es) 1999-01-27 2000-01-27 Compuestos de hidroxamato inverso como inhibidores de metaloproteasas matriciales.

Country Status (28)

Country Link
US (1) US20020007060A1 (enExample)
EP (1) EP1147101B1 (enExample)
JP (1) JP4718686B2 (enExample)
KR (1) KR100748010B1 (enExample)
CN (1) CN1222519C (enExample)
AR (1) AR029329A1 (enExample)
AT (1) ATE228122T1 (enExample)
AU (1) AU764383B2 (enExample)
BG (1) BG105782A (enExample)
BR (1) BR0007278A (enExample)
CA (1) CA2358951C (enExample)
CO (1) CO5150194A1 (enExample)
CZ (1) CZ20012591A3 (enExample)
DE (1) DE60000819T2 (enExample)
DK (1) DK1147101T3 (enExample)
ES (1) ES2187443T3 (enExample)
HK (1) HK1043115A1 (enExample)
HU (1) HUP0105477A2 (enExample)
IL (1) IL143713A0 (enExample)
NO (1) NO20013669L (enExample)
NZ (1) NZ512372A (enExample)
PL (1) PL349771A1 (enExample)
PT (1) PT1147101E (enExample)
SK (1) SK10582001A3 (enExample)
TR (1) TR200102159T2 (enExample)
TW (1) TWI225486B (enExample)
WO (1) WO2000044739A1 (enExample)
ZA (1) ZA200104979B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU2001298065A1 (en) * 2001-01-12 2003-09-02 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
EP1431285B1 (en) 2001-09-07 2009-01-07 Kaken Pharmaceutical Co., Ltd. Reverse hydroxamic acid derivatives
EP1896404B1 (en) * 2005-06-27 2014-09-17 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780386B1 (en) * 1995-12-20 2002-10-02 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
CA2358951A1 (en) 2000-08-03
AU2739100A (en) 2000-08-18
HK1043115A1 (zh) 2002-09-06
JP2002535398A (ja) 2002-10-22
IL143713A0 (en) 2002-04-21
HUP0105477A2 (hu) 2002-05-29
TR200102159T2 (tr) 2001-12-21
BG105782A (en) 2002-04-30
US20020007060A1 (en) 2002-01-17
SK10582001A3 (sk) 2001-12-03
AR029329A1 (es) 2003-06-25
NO20013669D0 (no) 2001-07-26
EP1147101A1 (en) 2001-10-24
WO2000044739A1 (en) 2000-08-03
PL349771A1 (en) 2002-09-09
NZ512372A (en) 2003-01-31
TWI225486B (en) 2004-12-21
ATE228122T1 (de) 2002-12-15
CN1339032A (zh) 2002-03-06
BR0007278A (pt) 2001-11-27
ZA200104979B (en) 2002-09-18
NO20013669L (no) 2001-09-27
EP1147101B1 (en) 2002-11-20
DE60000819D1 (de) 2003-01-02
CZ20012591A3 (cs) 2001-12-12
DE60000819T2 (de) 2003-09-04
CO5150194A1 (es) 2002-04-29
PT1147101E (pt) 2003-04-30
DK1147101T3 (da) 2003-03-10
AU764383B2 (en) 2003-08-14
CA2358951C (en) 2009-10-20
KR20010101709A (ko) 2001-11-14
CN1222519C (zh) 2005-10-12
KR100748010B1 (ko) 2007-08-09
JP4718686B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
PE20242071A1 (es) Compuestos moduladores de diacilglicerol quinasa
PE20230238A1 (es) Inhibidores de kras g12c
PE20201256A1 (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas
DOP2005000071A (es) "compuestos de metil-aril o heteroaril-amida sustituida"
PE20251071A1 (es) Inhibidores de kras
AR036213A1 (es) Derivados de 6-fenil-pirrolo[2,3-d]pirimidina, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de composiciones farmaceuticas
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
ES2304992T3 (es) Agentes antibacterianos de 3-aminoquinazolin-2,4-diona.
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
UY28878A1 (es) Compuestos de aril-o heteroarilamida ortosustituidos y composiciones
DOP2005000046A (es) Compuestos de acido alfa arilo o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1
ES2124545T3 (es) Azolidindionas como agentes antihiperglucemicos.
CO4980859A1 (es) Arilpiperazinas que tienen actividad sobre el receptor 1a de la serotonina
CO5640131A2 (es) Compuestos de n-formil-hidroxilamina como inhibidores de pdf
ES2187443T3 (es) Compuestos de hidroxamato inverso como inhibidores de metaloproteasas matriciales.
AR041864A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
ATE155792T1 (de) Ungesatigte 17-beta-substituierte-3-carboxy steroide
DK1390036T3 (da) Prostansyrederivater som midler til nedsættelse af intraokulært tryk
PE20232047A1 (es) Quinolinas y azaquinolinas como inhibidores de cd38
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
MA29559B1 (fr) Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
PE20250419A1 (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos
PE20251177A1 (es) Inhibidores heterociclicos de sik
CL2023001440A1 (es) Nuevos derivados de indazol acetileno
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them